Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

European Innovation Council · Running

LILY LILY: A Breakthrough Technology to Prevent Chemotherapy-Induced Hair Loss

Coordinator
Luminate Medical Limited, Ireland
Runs
1 October 2023 to 31 March 2026
Status
Running
EU funding
€2.5m
Total cost
€4.1m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190130710

What the project is doing

In the project's own words, from its summary on CORDIS.

Chemotherapy-induced alopecia (CIA) is hair loss associated with chemotherapy treatment for cancer. LILY is a portable, comfortable, and effective CIA prevention device that uses localised microvasculature compression therapy (LMCT) to prevent CIA. The LILY device uses this unique LMCT technique to reduce perfusion at the scalp and prevent the destructive action of chemotherapy on hair follicles. By applying a consistent low-level pressure (between 35 and 60 mmHg) to the local micro blood vessels, which could deliver chemotherapy drugs to fast-dividing hair follicles, the vessels are temporarily compressed, inhibiting drug delivery.

The device comprises a proprietary pneumatic bladder network design and soft robotics system with the ability to non-invasively induce vasoconstriction in superficial vessels of the scalp to mechanically control tissue perfusion, and an electronic control system for both patient management of the system and real-time feedback into the treatment protocol.

Topics

Who is involved

OrganisationCityCountryRole
Luminate Medical LimitedGalwayIrelandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI